View
228
Download
0
Category
Preview:
Citation preview
Revised Manuscript (M4:09934) Hart et al
The adenovirus E4orf6 protein inhibits DNA double strand break repair and
radiosensitizes human tumor cells in an E1B-55K-independent manner.
Lori S. Hart§¶, Steven M. Yannone#, Christine Naczki§, Joseph S. Orlando�, Stephen B. Waters¶,
Steven A. Akman¶, David J. Chen#, David Ornelles¶�, and Constantinos Koumenis§¶�*
Departments of §Radiation Oncology, ¶Cancer Biology, �Neurosurgery, and �Microbiology and
Immunology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
#Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
Corresponding Author: *Constantinos Koumenis, Section of Radiation Biology, NRC 412, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157. Phone: (336) 713-7637. Fax: (336) 713-7639. Email: ckoumeni@wfubmc.edu. Running Title: Ad5 E4orf6 Radiosensitizes Human Tumor Cells
Keywords. E4orf6, DNA-PK, DNA repair, radiosensitization, gene therapy
1
JBC Papers in Press. Published on October 26, 2004 as Manuscript M409934200
Copyright 2004 by The American Society for Biochemistry and Molecular Biology, Inc.
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
Summary
The adenoviral protein E4orf6 has been shown to inhibit both in vitro V(D)J recombination and
adenoviral DNA concatenation, two processes that rely on cellular DNA double strand break
repair (DSBR) proteins. Most of the known activities of E4orf6 during adenoviral infection
require its interaction with another adenoviral protein, E1B-55K. Here we report that E4orf6,
stably expressed in RKO human colorectal carcinoma cells or transiently expressed by
adenoviral vector in U251 human glioblastoma cells inhibits DSBR and induces significant
radiosensitization in the absence of E1B-55K. Expression of a mutant form of E4orf6 (L245P),
failed to radiosensitize RKO cells. E4orf6 reduced DSBR capacity in transfected and infected
cells, as measured by sublethal DNA damage repair assay and phosphorylated H2AX (γ-H2AX)
levels, respectively. Consistent with the inhibitory effect of E4orf6 on DSBR, expression of
wild-type but not mutant E4orf6 reduced recovery of a transfected, replicating reporter plasmid
(pSP189) in 293 cells, but did not increase the mutation frequency measured in the reporter
plasmid. The kinase activity of DNA-PKcs towards heterologous substrates was not affected by
expression of E4orf6; however, autophosphorylation of DNA-PKcs at Thr2609 following IR was
prolonged in the presence of E4orf6 compared to control-infected cells. Our results demonstrate
for the first time that E4orf6 expression hinders the cellular DNA repair process in mammalian
cells in the absence of E1B-55K or other adenoviral genes, and suggest that viral-mediated
delivery of E4orf6, combined with localized external beam radiation could be a useful approach
for the treatment of radioresistant solid tumors such as glioblastomas.
2
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
Introduction
DNA double strand breaks (DSBs1) occur naturally during DNA replication and V(D)J
recombination, but are also produced during the treatment of human malignancies with ionizing
radiation (IR) and genotoxic drugs. In mammalian cells, the predominant pathway for repairing
DSBs is non-homologous end joining (NHEJ). The DNA-dependent protein kinase (DNA-PK)
complex is required for NHEJ. This complex, which includes Ku70, Ku80 and the 450kDa
DNA-PK catalytic subunit (DNA-PKcs), recruits several other repair proteins including the
MRE11/Rad50/NBS1 (MRN) complex, XRCC4, and Ligase IV (1). Despite the large number of
proteins and seemingly redundant pathways involved in the processing of DNA damage, targeted
gene deletions or mutations of any of the NHEJ proteins in mice results in growth deficiency,
immune deficiency from defective V(D)J recombination, hypersensitivity to IR, neuronal
apoptosis, and in some cases tumorigenesis due to increased genomic instability (1,2). These
consequences of defective NHEJ demonstrate the importance of DSBR proteins in maintaining
genomic integrity and cellular viability. Conversely, the hypersensitivity of DSBR-deficient
cells to IR makes repair proteins an attractive target for radiosensitization of tumor cells with
localized beam radiation approaches (3).
Interestingly, adenoviral proteins have recently been shown to interfere with the NHEJ
pathway to prevent host cell-mediated ligation of the linear adenoviral DNA, which would
otherwise lead to viral DNA concatemer formation (4,5). During adenoviral infection, E4orf6
cooperates with E1B-55K to target p53 and MRE11 for degradation, preventing a p53-mediated
anti-viral response and inhibiting the NHEJ-dependent process of concatemer formation (4-6). It 1The abbreviations used are: DSBR, DNA double-strand break repair; DSBs, DNA double-strand breaks; NHEJ, non-homologous end joining; DNA-PK, DNA-dependent protein kinase; DNA-PKcs, DNA-PK catalytic subunit; MRN, MRE11/Rad50/Nbs1 complex; IR, ionizing radiation; SLDR, sublethal damage repair.
3
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
is likely that the ability of E4orf6 and E1B-55K to cooperate in suppressing concatemer
formation may have evolved as a means of bypassing host cell defenses against viral DNA
replication and productive infection. E4orf6, a 34kDa protein encoded by open reading frame 6
of the E4 gene, has been reported to interact with DNA-PKcs and to inhibit V(D)J recombination
in vitro (7), an NHEJ-dependent process that generates immunological diversity through DNA
rearrangements. Since these experiments were performed in 293 cells, which express E1B-55K,
it is unknown if E4orf6 alone can inhibit cellular DSBR or DNA-PKcs activity. The inhibition
of NHEJ proteins in suppressing concatemer formation and V(D)J recombination makes E4orf6
an attractive tool for inhibiting cellular NHEJ. Considering that radiation therapy is a frequent
treatment for solid tumors and proficient DSBR limits tumor cell kill in response to IR treatment
(8,9), the inhibition of DSBR proteins is an attractive approach for tumor radiosensitization
(10,11). Therefore, we examined the ability of E4orf6 to inhibit NHEJ and to radiosensitize
tumor cells.
Experimental Procedures
Cell Culture- All cell lines (American Type Culture Collection, Manassas, VA) were
incubated at 37ºC with 5%CO2. U251 cells were maintained with RPMI-1640 media, RKO cells
with McCoys5A, and M059 J and K cell lines with DMEM/F12, each supplemented with 10%
fetal bovine serum, L-glutamine, and penicillin/streptomycin. The M059 cell lines were also
supplemented with sodium bicarbonate (1.5g/L), nonessential amino acids, and sodium pyruvate.
RKO stable clones were established by transfection of plasmids (LipofectAMINE PLUS,
Invitrogen, Carlsbad, CA) and selection with neomycin (300µg/ml). Harvested RKO clones
were maintained in media supplemented with 100µg/ml neomycin.
4
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
Clonogenic Survival Assay- Clonogenic survival assays were performed as previously
described (12). For survival assays involving infections, U251 cells were plated in 35mm plates
in triplicate at equal density, infected the next day at an MOI predetermined to yield maximal
infectivity, and irradiated 48 hours later with a 137Cs source (dose rate of 4.41Gy/min) at a range
of IR doses. When unirradiated control plates were near confluency (at or near day 7 post-IR),
the cells were fixed and stained with crystal violet as previously described (12). Crystal violet
was solubilized in 33% acetic acid and the absorbance at 540nm was measured in triplicate for
each well as described by Bernardi et al (13).
Immunoblotting- RKO clones and infected cells were harvested as previously described
(12). For E4orf6, E1B-55K, p53, MRE11, and β-actin immunoblots, lysates (60µg total protein)
were resolved on 12% SDS-PAGE gels, transferred to PVDF membrane, blocked for 30 minutes
at room temperature, and incubated for one hour at room temperature with the following
antibodies: anti-E4orf6 antibody (MAb#3 at 1:100), anti-E1B-55K (9C10 at 1:4), anti-p53 (DO-1
at 1:5000; Santa Cruz Biotechnology, Santa Cruz, CA), anti-MRE11 (12-D7 at 1:5000;
GeneTex, San Antonio, TX), anti-β-actin (at 1:50,000; Sigma, St. Louis, MO). DNA-PKcs
lysates were resolved on 6% SDS-PAGE gels, transferred to nitrocellulose overnight at 25V, and
blotted with anti-DNA-PKcs monoclonal antibody (25-4 at 1:5000; NeoMarkers, Fremont, CA)
or anti-Thr2609 polyclonal DNA-PKcs antibody (1:1000) (14). Cells used in γ�H2AX
immunoblots were directly lysed in 1.5X SDS sample buffer, boiled for 10 minutes, and passed
through a 28 gauge syringe 3 times. Equal volumes were loaded on 15% SDS-PAGE gels,
transferred to PVDF, and membranes were incubated overnight at 4ºC with anti-γ-H2AX
antibody (1:5000; Upstate, Charlottesville, VA). All membranes were incubated with HRP-
conjugated anti-mouse or anti-rabbit secondary antibodies (Santa Cruz Biotechnology, Santa
5
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
Cruz, CA) and immunoreactive bands were detected using ECL Plus chemiluminescence
(Amersham Biosciences, Piscataway, NJ). Optical density of reactive bands was measured by
image analysis software (Scion Image; Scion Corporation, Frederick, MD) as previously
described (12).
Immunocytochemistry- Indirect immunofluorescence microscopy of RKO and U251
cells was performed as previously described (15) at 48 hours post-transfection or post-infection.
The cells were fixed in either methanol:acetone (1:1) or 2% paraformaldehyde, blocked with
TBS-BGT [137mM NaCl, 3mM KCl, 20 mM Tris, pH 7.6, 5.0mg/ml BSA, 1.0mg/ml glycine,
0.05% Tween-20, 0.02% sodium azide], and incubated with mouse monoclonal anti-E4orf6
antibody (MAb#3 at 1:100 in TBS-BGT) or rat monoclonal anti-E1B-55K (9C10 at 1:100 in
TBS-BGT) for 20 minutes at 37ºC. Primary antibody binding was detected with either Alexa
Fluor 488-conjugated anti-mouse or Alexa Fluor 568-conjugated goat-anti-rat secondary
antibodies (Molecular Probes, Eugene, OR). U251 cells were counterstained with Hoescht33342
(1µg/ml in TBS-BGT) or 4',6-diamidino-2-phenylindole (DAPI).
Mutagenicity Assay- Mutation frequency was measured in a replicating reporter plasmid
pSP189 originally described by Seidman and associates (16). The pSP189 shuttle vector was co-
transfected with a plasmid to express the wild-type E4orf6 or mutant L245P gene in 293 cells.
After two days, the shuttle vector was purified by the protocol of Hirt (17). Plasmid DNA was
purified and mutations within the 158 bp supF gene were identified by transforming the E. coli
strain MBL-50. Bacteria containing a mutant supF gene were counted after 48 hours of growth
on minimal media containing L-arabinose and ampicillin. The total number of transformants
was determined by plating appropriate dilutions of the cells on Luria broth plates containing
ampicillin. The amount of material used for each transformation was empirically adjusted so
6
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
that approximately one-half of 16 independent transformations yielded no supF-mutant colonies.
Mutation frequencies were calculated by application of the Poisson distribution. To quantify the
amount of replicated plasmid, the Hirt-purified DNA was treated with Dpn I, purified, and
limiting amounts of the Dpn I-treated DNA used to transform MBL-50 bacteria. The number of
transformants was enumerated after plating serial dilutions on Luria broth bacterial plates
supplemented with ampicillin. No kanamycin-resistant bacteria were generated from Dpn I-
treated DNA, confirming that the non-replicating plasmids were inactivated.
In Vitro DNA-PKcs Kinase Assays- This protocol is adapted from previously published
reports (18) and the SignaTECT DNA-Dependent Protein Kinase Assay System manufacturer
protocol (Promega, Madison, WI). Briefly, cell pellets were resuspended in extraction buffer,
lysed by 3 consecutive cycles of freeze/thawing, and cleared by centrifugation. The high-salt
lysates (50µL) were diluted by adding four volumes of dilution buffer. Equilibrated dsDNA-
cellulose (Sigma, St. Louis, MO) diluted 1:2 in wash buffer was added to each sample and
incubated for at least 30minutes on a rocker at 4ºC. Cellulose was pelleted and the extracted
supernatant was re-extracted with 40µL cellulose slurry. The combined pellets were resuspended
in wash buffer. The cellulose (10µL) was used in place of the enzyme samples in the
SignaTECT kinase reaction (Promega, Madison, WI). Terminated reactions were spotted on
biotinylated membrane (SAM2®; Promega, Madison, WI) and the membranes were washed as
described in the protocol. Measurement of radioactivity was performed with a scintillation
counter (LS5000CE; Beckman, Fullerton, CA).
Statistical Analysis- Where necessary, data was statistically analyzed to generate S.E.
values and determine level of significance using the two-tailed Student�s t-test.
7
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
Results
Stable expression of E4orf6 radiosensitizes RKO cells- To examine the effects of E4orf6
on human tumor cell radiosensitivity, we first established clones of RKO human colorectal
carcinoma cells stably expressing wild-type E4orf6, a control neomycin resistance gene, or
E4orf6-L245P, a non-functional variant during adenovirus infection (15). The wild-type E4orf6
expressed in the RKO cells directed E1B-55K to the nucleus (Figure 1A) and cooperated with
E1B-55K to target p53 and MRE11 for degradation (Figure 1B), indicating that functional
protein was expressed. In contrast, the E4orf6-L245P mutant failed to direct E1B-55K to the
nucleus and failed to cooperate with E1B-55K to target p53 and MRE11 for degradation (Figure
1). Interestingly, reduced levels of E1B-55K protein were observed in the control (neo) and
L245P cell lines infected with the E4-mutant virus dl1014 (Figure 1B). Because all the cells
were equally infected (data not shown), it seems likely that the decreased E1B-55K protein
levels may have resulted from diminished stability of the E1B-55K protein in the absence of a
functional E4orf6 protein. To our knowledge this is the first reported case of stable E4orf6
expression in mammalian cells.
In order to determine if E4orf6 increased the radiosensitivity of the RKO cells,
clonogenic survival was analyzed after exposure to a range of IR doses. Two independently
isolated clones expressing wild-type E4orf6 were significantly more radiosensitive (10-fold at
8Gy) than either a vector-transfected clone or an E4orf6-L245P mutant clone (Figure 2). E1B-
55K is not expressed in the clones, indicating that E4orf6 radiosensitizes RKO cells without
affecting p53 or MRE11 protein levels. The radiosensitization effect was quantified as a dose-
enhancement ratio (DER) of approximately 1.4 over the range of IR doses.
8
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
Transient expression of E4orf6 radiosensitizes U251 cells- Although E4orf6
radiosensitized two independent RKO clones, it remained possible that random integration of the
foreign DNA in the RKO clones, rather than E4orf6 expression contributed to the
radiosensitization effect (19). To test this, we measured the ability of E4orf6 to radiosensitize
human tumor cells following transient expression from a non-replicating and non-integrating
adenovirus, a viral vector that is frequently used in cancer gene therapy modalities. Both control
virus (vCMV-null) and E4orf6-expressing virus (vCMV-E4orf6) lack the E1 gene, which renders
them non-replicative (Figure 3A) (20). Although the vCMV-null virus contains an intact E4
promoter and gene, expression of the E4orf6 protein from the endogenous gene was not detected
by either immunoblotting (Figure 3B) or immunofluorescent microscopy (Figures 3C), as
expected in the absence of the E1 gene products. The vCMV-E4orf6 virus expresses E4orf6
from a CMV promoter and lacks the endogenous viral E4 gene (20), and therefore, lacks
expression of the other E4 gene products. U251 glioblastoma cells infected with vCMV-E4orf6
were significantly more radiosensitive than those infected with vCMV-null virus (Figure 4).
Thus, transient expression of E4orf6 from a non-integrating, non-replicating adenoviral vector
significantly radiosensitizes U251 cells, indicating that E4orf6 expression and not stable
integration is responsible for radiosensitization by E4orf6.
E4orf6 inhibits cellular DNA DSBR- The inhibition of clonogenic survival (Figures 2 and
4) and the reported interaction between E4orf6 and DNA-PKcs (7) led us to hypothesize that
E4orf6 radiosensitizes RKO and U251 cells by preventing repair of IR-induced DNA breaks. To
test this hypothesis, we measured sublethal damage repair (SLDR) in the RKO clones. The
SLDR assay is a variation of the standard clonogenic survival assay based on the fact that cell
survival increases with increasing amounts of time between two doses of sublethal IR, providing
9
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
that the cells can repair the initial IR damage prior to the second dose (21-23). RKO cells
expressing E4orf6 did not benefit from increased time between two radiation treatments of 3Gy
(Figure 5A). In contrast, the neomycin-transfected control cells demonstrated a two-fold
increase in survival when the two doses were separated by 6 hours. This result strongly suggests
that the E4orf6-expressing RKO clones have a decreased capacity for DSBR.
Recently, is was shown that γ�H2AX can serve as a quantitative measure of DSBs
because H2AX is phosphorylated at serine 139 in the region of the DSB and is subsequently
dephosphorylated following repair of the DNA break (24-27). DSBR in infected U251 cells was
assayed by measuring the levels of phosphorylation of histone 2AX at Ser139 (termed γ�H2AX)
by immunoblotting at various time points post-IR (28-31). U251 cells were infected with either
vCMV-null or vCMV-E4orf6 and irradiated with 4Gy at 48 hours post-infection. At several
time points post-irradiation, cells were harvested and analyzed for γ�H2AX by SDS-PAGE and
immunoblotting. Figure 5B shows that at 6 hours post-IR, a time at which more than 90% of
DSBs should have been repaired, the cells expressing E4orf6 contained substantially higher
levels of γ�H2AX compared with cells infected with control virus, suggesting that unrepaired
DSBs accumulate in the presence of E4orf6. This experiment was repeated with similar results
and immunoreactive bands were quantified, normalized to β�actin levels, and expressed as fold-
increase compared with the unirradiated control for each virus (Figure 5C). In addition, we have
analyzed the loss of phosphorylation of H2AX at Ser139 (termed �percent repair�) by examining
the difference between the 30 minute post-IR timepoint (consistently the maximum level) and
the 6 hour timepoint (the point at which most DSBR has occurred) (Figure 5D). In both cases,
E4orf6-expressing U251 cells retain significantly high levels of γ�H2AX indicative of
unrepaired DSBs.
10
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
E4orf6 expression does not increase mutation frequency- We have demonstrated that
E4orf6 radiosensitizes by inhibiting DSBR (measured by SLDR assay) leading to the
accumulation of DSBs (measured by γ-H2AX levels); however, it has been previously suggested
that expression of E4orf6 itself may be mutagenic based on the hprt test for mutagenicity (32).
To determine if the decreased capacity for DSBR was due to increased cellular mutation
frequency, 293 cells were transfected with empty expression vector, or a vector expressing the
wild-type E4orf6 or the mutant L245P gene and a replication-competent reporter vector, pSP189.
In a representative experiment (Table I), 293 cells transfected with the empty expression vector
and the pSP189 reporter vector exhibited a mutation frequency of 3.5×10-7 mutations per bp,
consistent with the background mutation frequency reported for this cell line (33). Expression of
the wild-type E4orf6 or mutant L245P variants did not increase the mutation frequency. By
contrast, exposure of vector-transfected cells to mutagenic levels of UV light (50 J/m2) increased
the mutation frequency by nearly two orders of magnitude. Similar results were obtained in two
independent experiments. Thus, although E4orf6 reportedly increases the mutation frequency
two-fold at the chromosomal hypoxanthine guanine phosphoribosyl transferase (hprt) locus in
the D422 Chinese hamster ovary cell line (32), it does not elicit point or frameshift mutations in
a replicating plasmid. However, the amount of reporter plasmid recovered from 293 cells
expressing the E4orf6 protein was significantly reduced. The results of two independent
experiments indicated that expression of E4orf6 in 293 cells for 48 hours reduced the amount of
recovered pSP189 reporter by 50% compared to that recovered from cells transfected with the
empty expression vector or the L245P construct (Table I). This result is consistent with the
ability of the E4orf6 but not L245P protein to block DSBR, as naturally occurring DNA breaks
are formed and repaired during plasmid replication.
11
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
E4orf6 does not inhibit the kinase activity of DNA-PKcs, but prolongs its
autophosphorylation following IR- Our results described thus far support a model in which
E4orf6 radiosensitizes cells by inhibiting DSBR, perhaps by inhibiting the DNA-PK complex
through a direct interaction with DNA-PKcs (7). The effect of E4orf6 on DNA-PK activity was
assessed by measuring the ability of DNA-PK to phosphorylate a p53-related peptide in vitro.
When expressed in U251 cells by an adenoviral vector, E4orf6 did not affect DNA-PK kinase
activity towards a heterologous substrate (Figure 6A). However, it remains controversial
whether p53-phosphorylation is an appropriate measure of DNA-PK activity with regards to
DNA repair and radioresistance because DNA-PK-dependent end-joining activity and radiation
resistance can be compromised while DNA-PK is still able to phosphorylate p53 (34,35).
Recently, the autophosphorylation of DNA-PKcs has been identified as a critical factor in
maintaining radioresistance, with either hypo- or hyper-autophosphorylation of DNA-PKcs
resulting in radiosensitization (14,36,37). Regulation of the autophosphorylation of DNA-PKcs
within a cluster of six serine and threonine sites is important in maintaining radioresistance (14).
Thus, we hypothesized that E4orf6 may affect DNA-PK autophosphorylation, which in
conjunction with subsequent dephosphorylation, is necessary for radioresistance.
Following treatment of infected U251s with IR, autophosphorylation of DNA-PKcs at
Thr2609 was measured over time by immunoblotting with a phospho-specific antibody.
Comparable amounts of Thr2609-phosphorylated DNA-PKcs accumulated in U251 cells
infected with either vCMV-E4orf6 or vCMV-null at early time points post-irradiation (Figure
6B). However, in contrast to vCMV-null infected cells, in which dephosphorylation was near
completion 6 hours post-irradiation, Thr2609-phosphorylated DNA-PKcs remained upregulated
in E4orf6-expressing cells, which is consistent with a radiosensitive phenotype. The experiment
12
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
was repeated two more times with similar results. Reactive bands from all three experiments
were quantified and normalized to total DNA-PKcs levels (Figure 6C).
Discussion
Our data identifies the adenoviral protein E4orf6 as a radiosensitizer of human tumor
cells. We have demonstrated both stable and transient expression of E4orf6 in two different
tumor cell lines. This radiosensitization is occurring in the absence of E1B-55K, the adenoviral
protein that interacts with E4orf6, an interaction that is required for the degradation of MRE11
and p53 and the inhibition of adenoviral DNA concatemer formation (5,6). Our data reveals that
E4orf6 is able to radiosensitize tumor cells by inhibiting cellular DNA DSBR in the absence of
E1B-55K, and therefore, independent of MRE11 and p53 protein levels.
A recent study reported that transient transfection of E4orf6 in a variety of tumor cell
lines, including RKO cells, did not result in significant radiosensitization (19). We believe that
this discrepancy may result from the fact that following transient transfection not all of the cells
express E4orf6, which would be important in order to accurately assess clonogenic survival
following treatment with clinically relevant doses of IR. Furthermore, the lack of
radiosensitization by the E4orf6-L245P mutant suggests that the wild-type activity or the proper
conformation of E4orf6 is necessary for its radiosensitizing capabilities (the L245P mutation was
introduced to disrupt a critical amphipathic alpha helix in the E4orf6 protein) (15). Finally, the
similar radiosensitization effect measured in two independently selected wild-type E4orf6 clones
and the ability of adenoviral-expressed non-integrated E4orf6 to produce a similar effect,
suggests that the radiosensitizing property was not the result of positional effects from genomic
integration.
13
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
Our results also argue against the possibility that E4orf6 is mutagenic. The levels of γ�
H2AX (DSBs) are similar between vCMV-null and vCMV-E4orf6 infected cells in the absence
of IR and E4orf6 does not increase the frequency of mutations (point or frameshift) in 293 cells.
However, E4orf6 plasmid recovery is reduced when compared with control plasmids, which is
consistent with our theory of an inhibition of cellular DSBR by E4orf6. More specifically,
during episomal DNA replication, type II topoisomerases transiently introduce double-strand
breaks in the nascent molecules (38). If any of the plasmids acquire a double-strand break
during this process, the inhibition of DSBR by the E4orf6 protein may prevent rejoining of the
DNA, thereby reducing the number of intact, replicated plasmids recovered.
We have found that expression of E4orf6, while not affecting the kinase activity of DNA-
PKcs with regards to heterologous substrates, prolongs the autophosphorylation of DNA-PKcs at
Thr2609. These data lead us to propose a model (Figure 7) in which E4orf6 inhibits the late
stages of repair as DNA-PKcs remains able to phosphorylate itself in response to DNA damage
and repair, but dephosphorylation of DNA-PKcs at Thr2609 is prevented. DNA-PKcs
autophosphorylation is Ku-dependent (14) and is proposed to occur as a signal for the repair
complex to undergo a conformational change conducive to ligation and/or post-ligation
dissociation from the DNA (34,35). Two possible modes of action for E4orf6 include either A) a
physical interaction with DNA-PKcs, or B) an inhibition of protein phosphatase 5, the
phosphatase implicated in the dephosphorylation of DNA-PKcs at Thr2609 (36). Although
E4orf6 has been shown to require E1B-55K to degrade MRE11 and prevent concatemer
formation (5), our model is consistent with these findings in that regardless of the state of DSB
ligation, damage-induced signaling is sustained by phosphorylation of H2AX at Ser139 and
DNA-PKcs at Thr2609 in the presence of E4orf6 alone. It has been recently proposed that
14
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
sustained autophosphorylation of DNA-PKcs results in a radiosensitive phenotype (14,34)
possibly by signaling incomplete DNA repair and initiating growth arrest or cell death. Our data
is in agreement with this model.
In summary, we have demonstrated that the adenovirus E4orf6 protein radiosensitizes
human tumor cells by inhibiting DSBR without affecting p53 or MRE11 protein levels. E4orf6
promotes the accumulation of DSBs as observed by prolonged phosphorylation of both H2AX at
Ser139 and DNA-PKcs at Thr2609. Our results show for the first time that an adenoviral protein
has radiosensitizing properties by inhibiting the repair of damaged host cell DNA in vivo. A
model consistent with our data and that of other investigators is that E4orf6 promotes viral DNA
replication by inhibiting cellular NHEJ in an effort to prevent concatenation of viral DNA
(4,5,7). Consequently, overexpression of E4orf6 is sufficient to inhibit the NHEJ response to IR-
induced cellular DSBs thereby radiosensitizing the host cell. The ability of E4orf6 to inhibit the
activity of repair proteins other than DNA-PK has not yet been explored. It remains possible that
E4orf6 is able to inhibit MRE11 function without degrading it (a process that requires E1B-
55K). Future experiments will test such possibilities.
The significant radiosensitization achieved at clinically relevant doses (2-8Gy) by E4orf6
has promising implications for improving radiation therapy, especially in radioresistant tumors
such as glioblastomas. It is conceivable that E4orf6 delivered by a viral vector or by non-viral
methods could substantially improve the cytotoxic effects of localized beam radiation therapy,
such as gamma knife radiosurgery.
15
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
References
1. Smith, G., and Jackson, S. P. (1999) Gen. and Dev. 13, 916-934
2. Sekiguchi, J. M., and Alt, F. W. (1999) Quant. Biol. 64, 169-181
3. Buchsbaum, D. J., Raben, D., Stackhouse, M. A., Khazaeli, M. B., Rogers, B. E.,
Rosenfeld, M. E., Liu, T., and Curiel, D. T. (1996) Gene Therapy 3(12), 1042-68
4. Weiden, M., and Ginsberg, H. (1994) Proc. Natl. Acad. Sci. 91(1), 153-157
5. Stracker, T. H., Carson, C. T., and Weitzman, M. D. (2002) Nature 418, 348-352
6. Querido, E., Blanchette, P., Yan, Q., Kamura, T., Morrison, M., Boivin, D., Kaelin, W.
G., Conaway, R. C., Conaway, J. W., and Branton, P. E. (2001) Gen. and Dev. 15(23),
3104-3117
7. Boyer, J., Rohleder, K., and Ketner, G. (1999) Virology 263, 307-312
8. Hendry, J. H. (2001) Radiotherapy and Oncology 59(2), 117-126
9. Ader, I., Muller, C., Bonnet, J., Favre, G., Cohen-Jonathan, E., Salles, B., and Toulas, C.
(2002) Oncogene 21(42), 6471-6479
10. Li, S., Takeda, Y., Wragg, S., Barrett, J., Phillips, A., and Dynan, W. S. (2003) Nucl.
Acids. Res. 31(20), 5848-5857
11. Marangoni, E., Le Romancer, M., Foray, N., Muller, C., Douc-Rasy, S., Vaganay, S.,
Abdulkarim, B., Barrois, M., Calsou, P., Bernier, J., Salles, B., and Bourhis, J. (2000)
Cancer Gen. Ther. 7(2), 339-346
12. Koumenis, C., Naczki, C., Koritzinsky, M., Rastani, S., Diehl, A., Sonenberg, N.,
Koromilas, A., and Wouters, B. G. (2002) Mol. Cell. Biol. 22(21), 7405-7416
13. Bernardi, R. J., Trump, D. L., Yu, W.-D., McGuire, T. F., Hershberger, P. A., and
Johnson, C. S. (2001) Clin. Cancer Res. 7(12), 4164-4173
16
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
14. Chan, D. W., Chen, B. P.-C., Prithivirajsingh, S., Kurimasa, A., Story, M. D., Qin, J., and
Chen, D. J. (2002) Gen. and Dev. 16, 2333-2338
15. Orlando, J. S., and Ornelles, D. A. (2002) J. Virol. 76(3), 1475-1487
16. Parris, C. N., and Seidman, M. M. (1992) Gene 117, 1-5
17. Hirt, B. (1969) J. Mol. Biol. 40, 141-144
18. Finnie, N. J., Gottlieb, T. M., Blunt, T., Jeggo, P. A., and Jackson, S. P. (1996)
Physiological transactions of the Royal Society of London, Series B, Biological Sciences
351, 173-179
19. Collis, S. J., Ketner, G., Hicks, J. L., Nelson, W. G., Demarzo, A. M., and DeWeese, T.
L. (2003) Int. J. Radiat. Biol. 79, 53-60
20. Nicolas, A. L., Munz, P. L., Falck-Pedersen, E., and Young, C. S. (2000) Virology 266,
211-224
21. Elkind, M. M. (1988) Radiat. Res. 114, 425-428
22. Amorino, G. P., Freeman, M. L., and Choy, H. (2000) Rad. Res. 153(4), 384-391
23. Amorino, G. P., Freeman, M. L., Carbone, D. P., Lebwohl, D. E., and Choy, H. (1999)
International Journal of Radiation Oncology*Biology*Physics 44(2), 399-405
24. Nazarov, I. B., Smirnova, A. N., Krutilina, R. I., Svetlova, M. P., Solovjeva, L. V.,
Nikiforov, A. A., Oei, S. L., Zalenskaya, I. A., Yau, P. M., Bradbury, E. M., and Tomilin,
N. V. (2003) Radiat. Res. 160, 309-317
25. Bonner, W. M. (2003) Proc. Natl. Acad. Sci. 100(9), 4973-4975
26. MacPhail, S. H., Banath, J. P., Yu, Y., Chu, E., and Olive, P. L. (2003) Radiation
Research 159(6), 759-767
17
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
27. Olive, P. L., and Banath, J. P. (2004) International Journal of Radiation
Oncology*Biology*Physics 58(2), 331-335
28. Watanabe, F., Fukazawa, H., Masutani, M., Suzuki, H., Teraoka, H., Mizutani, S., and
Uehara, Y. (2004) Biochemical and Biophysical Research Communications 319(2), 596-
602
29. Siino, J. S., Nazarov, I. B., Zalenskaya, I. A., Yau, P. M., Bradbury, E. M., and Tomilin,
N. V. (2002) FEBS Letters 527(1-3), 105-108
30. Rogakou, E. P., Boon, C., Redon, C., and Bonner, W. M. (1999) J. Cell. Biol. 146(5),
905-916
31. Bassing, C. H., Chua, K. F., Sekiguchi, J., Suh, H., Whitlow, S. R., Fleming, J. C.,
Monroe, B. C., Ciccone, D. N., Yan, C., Vlasakova, K., Livingston, D. M., Ferguson, D.
O., Scully, R., and Alt, F. W. (2002) Proc. Natl. Acad. Sci. 99(12), 8173-8178
32. Nevels, M., Tauber, B., Spruss, T., Wolf, H., and Dobner, T. (2001) J. Virol. 75(7), 3089-
3094
33. Akman, S. A., Sander, F., and Garbutt, K. (1996) Carcinogenesis 17, 2137-2141
34. Ding, Q., Reddy, Y. V. R., Wang, W., Woods, T., Douglas, P., Ramsden, D. A., Lees-
Miller, S. P., and Meek, K. (2003) Mol. Cell. Biol. 23(16), 5836-5848
35. Block, W. D., Yu, Y., Merkle, D., Gifford, J. L., Ding, Q., Meek, K., and Lees-Miller, S.
P. (2004) Nucl. Acids. Res. 32(14), 4351-4357
36. Wechsler, T., Chen, B. P. C., Harper, R., Morotomi-Yano, K., Huang, B. C. B., Meek,
K., Cleaver, J. E., Chen, D. J., and Wabl, M. (2004) Proc. Natl. Acad. Sci. 101(5), 1247-
1252
18
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
37. Douglas, P., Sapkota, G. P., Morrice, N., Yu, Y., Goodarzi, A. A., Merkle, D., Meek, K.,
Alessi, D. R., and Lees-Miller, S. P. (2002) Biochem. J. 368, 243-251
38. Halmer, L., and Gruss, C. (1997) Mol. Cell. Biol. 17(5), 2624-2630
Acknowledgements. We would like to thank C.S. Young for the generous donation of viruses
and Drs. Karin Drotschmann, Doug Lyles, and Heidi Chial for critical reading of the manuscript.
This work was supported in part by grants ARG0037 (CK) from the North Carolina
Biotechnology Center and CA77342 (DO) from the National Cancer Institute. JSO was
supported in part by NIH training grant T32 AI07401 to the Department of Microbiology and
Immunology. LSH would like to personally thank Drs. Pizzorno and Chernin for their guidance.
Note: J. S. Orlando is currently at the Department of Medicine, Harvard Medical School, 99 Brookline Ave. RN132, Boston MA, 02215. S. B. Waters is currently at the Curriculum in Toxicology, The University of North Carolina, Chapel Hill NC 27599.
19
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
Figure Legends
Figure 1. Stable expression of functional E4orf6 in RKO cells. (A) Wild-type E4orf6 stably
expressed in RKO cells is functional as measured by localization of E1B-55K to the nucleus. The
stable RKO clones (neomycin vector control, E4orf6, E4orf6-L245P) were transfected with a
plasmid expressing E1B-55K and analyzed for expression and localization of E4orf6 and E1B-
55K by indirect immunofluorescence microscopy. Total cells in the field are represented by DIC
and counterstained with 4',6-diamidino-2-phenylindole (DAPI). (B) Stable RKO clones
expressing wild-type E4orf6 exhibit E1B-55K-dependent degradation of p53 and MRE11. The
RKO stable clones were infected with one of three adenoviruses in order to supply the clones
with E1B-55K and/or E4orf6: dl309 (wild-type Ad), expresses both E1B-55K and E4orf6;
dl1014, expresses wild-type E1B-55K but lacks E4orf6 expression; dl1017, deficient at
expressing both E1B-55K and E4orf6. The infected clones were harvested for immunoblot to
analyze the stability of p53 and MRE11 protein levels. Early and late passage numbers of wild-
type E4orf6 clone 4 were used to demonstrate that E4orf6 expression remains functional at late
passage.
Figure 2. Stable expression of functional E4orf6 radiosensitizes RKO cells. The RKO clones
(neomycin vector, closed circles; E4orf6 clone 4, open circle; E4orf6 clone 1, closed triangle;
and E4orf6-L245P clone 2, open triangle) were plated at low density and treated with ionizing
radiation. Surviving fraction was normalized by plating efficiency and plotted on a semi-log
scale. Error bars represent SEM values.
20
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
Figure 3. Transient expression of E4orf6 via infection with a non-replicating adenoviral
vector. (A) Diagram of E4orf6-expressing and control adenovirus genomes. Both viruses lack
the E1 region rendering them non-replicative. (B and C) E4orf6 expression from vCMV-E4orf6
and not vCMV-null virus. U251 glioblastoma cells were infected with either vCMV-null or
vCMV-E4orf6 at an MOI sufficient to infect more than 95% of the cells. (B) At 48 hrs post-
infection, the cells were harvested for immunoblotting for E4orf6 protein levels. β�actin was
used as a loading control. (C) At 48 hrs post-infection the cells were fixed for indirect
immunofluorescence microscopy to identify E4orf6-expressing cells. Cells were counterstained
with Hoescht33342.
Figure 4. Transient expression of E4orf6 via infection with a non-replicating adenoviral
vector radiosensitizes U251 glioblastoma cells. U251 cells were plated at equal density, mock
infected (closed circles) or infected with either vCMV-null (open triangles) or vCMV-E4orf6
(closed squares), and scored for long-term cell survival by crystal violet staining. Absorbance
values were normalized to survival at 0 Gy for each infection condition. Significant
radiosensitization as determined by a two-tailed Student�s t test (n=3; *p<0.05, **p<0.005) is
marked with the appropriate asterisk.
Figure 5. Both stable and transient expression of E4orf6 inhibits DSBR in response to
ionizing radiation. (A) A sublethal DNA damage repair assay (SLDR) was performed by
plating the RKO clones at low density and irradiating with two 3 Gy doses of gamma radiation
separated by the indicated time points. Surviving colonies were normalized to T0 (no time
between doses). Values are represented by fold-increase in survival with time and each value
21
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
represents the average of three plates. The asterisk represents a significant difference in survival
as determined by Student�s t test (n=3, *p<0.05). (B) E4orf6 inhibits DSBR as measured by γ�
H2AX levels. U251 cells were irradiated with 4Gy at 48 hrs post-infection. At the given time
points post-irradiation, the cells were harvested for immunoblotting with anti- γ-H2AX
antibodies. Immunoblotting with β-actin was used as a loading control. (C) The immunoreactive
bands from three independent γ-H2AX immunoblots were quantified using Scion Image
software, normalized to β-actin, and expressed as -fold increase in γ-H2AX compared with the
unirradiated control for each virus (*p<0.01). (D) The loss of phosphorylation from 30 minutes
to 6 hours was analyzed from the data in (C) to yield percent repair values (*p<0.005).
Table I. E4orf6 decreases the recovery of plasmid without affecting mutation frequency.
The average amount of pSP189 plasmid recovered is expressed as a percentage of the plasmid
recovered from cells transfected with the empty expression vector. The results of two
independent experiments are shown in parentheses.
Figure 6. E4orf6 does not inhibit the kinase activity of DNA-PKcs towards heterologous
substrates, but prolongs autophosphorylation of DNA-PKcs at Thr2609. (A) Mock, vCMV-
null, or vCMV-E4orf6 infected U251 cells were tested for in vitro kinase activity on a p53
peptide. Wortmannin (30µM for 3 hours) treated U251 cells served as a positive control for
kinase inhibition and M059J and M059K cell lysates served as negative and positive controls,
respectively, for the function of the assay. (B) U251 cells infected with either vCMV-null or
vCMV-E4orf6 were irradiated with 20Gy and harvested at the given time points post-irradiation
for immunoblotting with a Thr2609 phospho-specific antibody of DNA-PKcs. A 20Gy IR dose
was chosen for this experiment, due to the relatively low affinity of the phospho-specific
22
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Revised Manuscript (M4:09934) Hart et al
23
antibody. An in vitro kinase reaction sample was loaded as a positive control for P-Thr2609 and
total DNA-PKcs was used as a loading control. (C) The immunoreactive bands from three
independent experiments were quantified using Scion Image software and normalized to total
DNA-PKcs. Consistent with previously published reports (36), in some cases P-Thr2609 became
partially degraded before 360 minutes post-IR, in which case we included both bands (450 kDa
and 250 kDa) in our analysis of both viruses. The data was analyzed for significance by a two-
tailed Student�s t test (n=3, *p<0.001).
Figure 7. Model of the inhibition of the late stages of DNA repair by E4orf6. In the presence
of E4orf6, cells retain their ability to phosphorylate H2AX at Ser139 (an early event) and
undergo Ku-dependent DNA-PKcs autophosphorylation at Thr2609 (a late event). The
autophosphorylation step is thought to induce a conformational change in the repair complex
preparing it for ligation and dissociation of the proteins from the DNA (34,35). However, these
proteins remain phosphorylated at times when efficient repair would be complete and H2AX and
DNA-PKcs would otherwise be dephosphorylated. Therefore, E4orf6 is most likely inhibiting
the repair process at the late stages, by preventing ligation and/or inhibiting the
dephosphorylation which would otherwise signal complete repair and result in cell survival. Our
model is in agreement with and partially adapted from Block et al (35).
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
control wild type E4orf6 E4orf6-L245PA Clone 1 Clone 1 Clone 4 Clone 2
DIC
DAPI
E4orf6
E1B-55K
3X inset
Red/Green Merge
neo neo L245P
E4orf6
.4 ea
rly
E4orf6
.4 lat
e
Cell line
Virus dl309 dl1014 dl1017
E4orf6
p53
MRE11
ß-actin
E1B-55kD
neo L245P
E4orf6
.4ea
rly
E4orf6
.4 lat
e
B
Figure 1
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
IR Dose (Gy)
0 2 4 6 8
Sur
vivi
ng F
ract
ion
0.001
0.01
0.1
1 RKO.neo.1RKO.E4orf6.4RKO.E4orf6.1RKO.L245P.2
Figure 2
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
AvCMV-null
CMVp
E4p∆E1A ∆E1B
CMVp
∆E1A ∆E1B
∆E4E4orf6vCMV-E4orf6
E4orf6
dl309Moc
kvC
MV-null
β-Actin
vCMV-E4orf6
B
C
vCMV-null
vCMV-E4orf6
Hoescht33342 E4orf6 Combined
Figure 3
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Dose (Gy)
0 2 4 6 8
Sur
vivi
ng F
ract
ion
(Nor
mal
ized
)
0.01
0.1
1MockNullE4orf6
**
*
Figure 4
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
A
B
γ-H2AX
β-actin
vCMV-null vCMV-E4orf60Gyt post-IR (min) 5 30 360 5 30 3600Gy
0.5
1.5
2.5
0 2 4 6Time (h) between 3Gy Doses
E4orf6.1Neo.1
*Fo
ld In
crea
se in
Sur
viva
l
C D
0
2
4
6
8
10
0Gy 5 30 360
Time Post-IR (min)
Fold
Incr
ease
in p
hos/
n (E
/C)
vCMV-nullvCMV-E4orf6 *
0
20
40
60
80
100
6hr
Time Post-IR
% R
epai
r (no
rmal
ized
) vCMV-nullvCMV-E4orf6
*
Figure 5
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
0no plasmid
100Vector
108 (118.9, 97.1)E4orf6-L245P
49 (46.1, 51.9)E4orf6
Average (%)PlasmidPlasmid Recovery
2.5x10-5Vector/UV
2.3x10-7E4orf6-L245P
4.3x10-7E4orf6
3.5x10-7Vector
Mut Frequency (mut/bp)Plasmid
Mutation Frequency
Table I
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
P-Thr2609
DNA-PKcs
IR 20Gy - + + - + +t post-IR (min) - 30 360 - 30 360
In vi
tro vCMV-null vCMV-E4orf6B
0
0.2
0.4
0.6
0.8
1
1.2
mock
vCMV-null
vCMV-orf6
wortman
n.
M059J
M059K
Kin
ase
activ
ity
(Nor
m.)
A
00.20.40.60.8
11.21.41.61.8
0Gy 30 360
Time Post-IR (min)
OD
(nor
mal
ized
to to
tal
DN
A-P
K)
vCMV-nullvCMV-E4orf6
*C
Figure 6
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
IRIR
H2AX H2AX
P
PPP P
H2AX
P
H2AX
PDNA-PK
PDNA-PK
E4orf6E4orf6
Figure 7
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Waters, Steven A. Akman, David J. Chen, David Ornelles and Constantinos KoumenisLori S. Hart, Steven M. Yannone, Christine C. Naczki, Joseph S. Orlando, Stephen B.
radiosensitizes human tumor cells in an E1B-55K-independent mannerThe adenovirus E4orf6 protein inhibits DNA double strand break repair and
published online October 26, 2004J. Biol. Chem.
10.1074/jbc.M409934200Access the most updated version of this article at doi:
Alerts:
When a correction for this article is posted•
When this article is cited•
to choose from all of JBC's e-mail alertsClick here
by guest on April 8, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Recommended